{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:45:25Z","timestamp":1792043125813,"version":"4.4.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.13070","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T15:32:47Z","timestamp":1653060767000},"page":"e2213070","source":"Crossref","is-referenced-by-count":96,"title":["Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines"],"prefix":"10.1001","volume":"5","author":[{"given":"Timothy A.","family":"Yap","sequence":"first","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya","family":"Ashok","sequence":"additional","affiliation":[{"name":"Tempus Labs Inc, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Stoll","sequence":"additional","affiliation":[{"name":"Tempus Labs Inc, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Mauer","sequence":"additional","affiliation":[{"name":"Tempus Labs Inc, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa M.","family":"Nepomuceno","sequence":"additional","affiliation":[{"name":"Tempus Labs Inc, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly L.","family":"Blackwell","sequence":"additional","affiliation":[{"name":"Tempus Labs Inc, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy E.","family":"Garber","sequence":"additional","affiliation":[{"name":"The Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"issue":"1","key":"zoi220387r1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13073-019-0703-1","article-title":"Molecular profiling for precision cancer therapies.","volume":"12","author":"Malone","year":"2020","journal-title":"Genome Med"},{"issue":"4","key":"zoi220387r2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1001\/jamaoncol.2020.7987","article-title":"Assessment of clinical benefit of integrative genomic profiling in advanced solid tumors.","volume":"7","author":"Cobain","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"zoi220387r3","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1200\/PO.20.00048","article-title":"Clinical utilization, utility, and reimbursement for expanded genomic panel testing in adult oncology.","volume":"4","author":"Hsiao","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"zoi220387r4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 Trial.","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov"},{"issue":"5","key":"zoi220387r5","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"issue":"22","key":"zoi220387r6","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","article-title":"Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.","volume":"18","author":"Tsimberidou","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"35","key":"zoi220387r7","doi-asserted-by":"publisher","first-page":"56491","DOI":"10.18632\/oncotarget.v7i35","article-title":"Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.","volume":"7","author":"Radovich","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"zoi220387r8","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41587-019-0259-z","article-title":"Integrated genomic profiling expands clinical options for patients with cancer.","volume":"37","author":"Beaubier","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"19","key":"zoi220387r9","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy.","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"24","key":"zoi220387r10","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.20.03661","article-title":"Therapeutic implications of germline testing in patients with advanced cancers.","volume":"39","author":"Stadler","year":"2021","journal-title":"J Clin Oncol"},{"issue":"25","key":"zoi220387r11","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer.","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi220387r12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome.","volume":"7","author":"Samadder","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi220387r13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ygyno.2018.10.003","article-title":"Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer.","volume":"151","author":"Naumann","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"9","key":"zoi220387r15","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.6004\/jnccn.2019.0044","article-title":"NCCN guidelines insights: genetic\/familial high-risk assessment: colorectal, version 2.2019.","volume":"17","author":"Gupta","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"zoi220387r17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.2017.11137","article-title":"Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing.","volume":"318","author":"Mandelker","year":"2017","journal-title":"JAMA"},{"issue":"10","key":"zoi220387r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.19452","article-title":"Yield and utility of germline testing following tumor sequencing in patients with cancer.","volume":"3","author":"Lincoln","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi220387r19","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/annonc\/mdw018","article-title":"Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.","volume":"27","author":"Meric-Bernstam","year":"2016","journal-title":"Ann Oncol"},{"issue":"24","key":"zoi220387r20","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.18632\/oncotarget.v10i24","article-title":"Clinical validation of the Tempus xT next-generation targeted oncology sequencing assay.","volume":"10","author":"Beaubier","year":"2019","journal-title":"Oncotarget"},{"issue":"40","key":"zoi220387r21","doi-asserted-by":"publisher","first-page":"25826","DOI":"10.18632\/oncotarget.v9i40","article-title":"Clinical validation of the Tempus xO assay.","volume":"9","author":"Beaubier","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"zoi220387r22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/gim.2016.190","article-title":"Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.","volume":"19","author":"Kalia","year":"2017","journal-title":"Genet Med"},{"issue":"1","key":"zoi220387r24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1001\/jamaoncol.2015.5208","article-title":"Germline variants in targeted tumor sequencing using matched normal DNA.","volume":"2","author":"Schrader","year":"2016","journal-title":"JAMA Oncol"},{"issue":"16","key":"zoi220387r25","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1158\/1078-0432.CCR-16-0015","article-title":"Germline analysis from tumor-germline sequencing dyads to identify clinically actionable secondary findings.","volume":"22","author":"Seifert","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"283","key":"zoi220387r26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa7161","article-title":"Personalized genomic analyses for cancer mutation discovery and interpretation.","volume":"7","author":"Jones","year":"2015","journal-title":"Sci Transl Med"},{"issue":"5","key":"zoi220387r27","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1001\/jamaoncol.2015.5699","article-title":"Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors.","volume":"2","author":"Parsons","year":"2016","journal-title":"JAMA Oncol"},{"issue":"9","key":"zoi220387r28","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jama.2015.10080","article-title":"Integrative clinical sequencing in the management of refractory or relapsed cancer in youth.","volume":"314","author":"Mody","year":"2015","journal-title":"JAMA"},{"issue":"24","key":"zoi220387r29","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","article-title":"Germline mutations in predisposition genes in pediatric cancer.","volume":"373","author":"Zhang","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi220387r30","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1073\/pnas.68.4.820","article-title":"Mutation and cancer: statistical study of retinoblastoma.","volume":"68","author":"Knudson","year":"1971","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"zoi220387r31","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer.","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi220387r32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors.","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"issue":"27","key":"zoi220387r33","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors.","volume":"38","author":"Yap","year":"2020","journal-title":"J Clin Oncol"},{"key":"zoi220387r14","unstructured":"National Comprehensive Cancer Network. Treatment by cancer type. Accessed September 8, 2021. https:\/\/www.nccn.org\/guidelines\/category_1"},{"key":"zoi220387r16","unstructured":"National Comprehensive Cancer Network. Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic. Accessed August 26, 2021. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=2&id=1503"},{"key":"zoi220387r23","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Accessed August 23, 2021. https:\/\/www.r-project.org\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2792499\/yap_2022_oi_220387_1652286061.41926.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T15:32:51Z","timestamp":1653060771000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2792499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.13070","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]}}}